Real-world Evidence of Prolonged Apixaban Treatment of Unprovoked Venous Thromboembolism

Study identification

• EU PAS number:
  EUPAS25305
• Study ID:
  31921
• Official title and acronym:
  Real-world Evidence of Prolonged Apixaban Treatment of Unprovoked Venous Thromboembolism
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study description:
  The objectives of this study are to describe patient characteristics, treatment patterns and outcomes among unprovoked VTE patients who received apixaban treatment and either continued or discontinued apixaban after 6 months
• Study status:
  Finalised

Study timelines

Date when funding contract was signed

Planned:03/01/2018

Actual:20/03/2018

Study start date

Planned:21/08/2018

Actual:18/09/2018

Data analysis start date

Planned:31/08/2018

Actual:15/10/2018

Date of final study report

Planned:01/12/2019

Actual:31/07/2019

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Pfizer/BMS

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable